Starpharma Holdings Limited (SPHRF)
USD 0.06
(7.53%)
USD 0.06
(7.53%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 36.81 Million AUD | -29.32% |
| 2023 | 52.08 Million AUD | -21.29% |
| 2022 | 66.17 Million AUD | -9.64% |
| 2021 | 73.23 Million AUD | 87.41% |
| 2020 | 39.07 Million AUD | -20.02% |
| 2019 | 48.85 Million AUD | -16.5% |
| 2018 | 58.51 Million AUD | -12.13% |
| 2017 | 66.59 Million AUD | 12.79% |
| 2016 | 59.03 Million AUD | 33.02% |
| 2015 | 44.38 Million AUD | 20.4% |
| 2014 | 36.86 Million AUD | -24.07% |
| 2013 | 48.55 Million AUD | -10.54% |
| 2012 | 54.26 Million AUD | 82.06% |
| 2011 | 29.8 Million AUD | -20.66% |
| 2010 | 37.56 Million AUD | 30.23% |
| 2009 | 28.84 Million AUD | 17.01% |
| 2008 | 24.65 Million AUD | -18.97% |
| 2007 | 30.42 Million AUD | 21.63% |
| 2006 | 25.01 Million AUD | 100.11% |
| 2005 | 12.49 Million AUD | -32.4% |
| 2004 | 18.49 Million AUD | 72.56% |
| 2003 | 10.71 Million AUD | -43.18% |
| 2002 | 18.85 Million AUD | -27.53% |
| 2001 | 26.02 Million AUD | -10.42% |
| 2000 | 29.05 Million AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 36.81 Million AUD | -16.2% |
| 2024 Q4 | 36.81 Million AUD | 0.0% |
| 2024 FY | 36.81 Million AUD | -29.32% |
| 2024 Q1 | 43.93 Million AUD | -33.61% |
| 2024 Q2 | 43.93 Million AUD | 0.0% |
| 2023 Q1 | 57.64 Million AUD | -12.89% |
| 2023 FY | 52.08 Million AUD | -21.29% |
| 2023 Q4 | 66.17 Million AUD | 27.05% |
| 2023 Q3 | 52.08 Million AUD | -9.65% |
| 2023 Q2 | 57.64 Million AUD | 0.0% |
| 2022 FY | 66.17 Million AUD | -9.64% |
| 2022 Q4 | 66.17 Million AUD | 0.0% |
| 2022 Q2 | 67.32 Million AUD | 0.0% |
| 2022 Q3 | 66.17 Million AUD | -1.71% |
| 2022 Q1 | 67.32 Million AUD | -8.08% |
| 2021 Q2 | 77.98 Million AUD | 0.0% |
| 2021 Q1 | 77.98 Million AUD | 99.56% |
| 2021 Q3 | 73.23 Million AUD | -6.09% |
| 2021 Q4 | 73.23 Million AUD | 0.0% |
| 2021 FY | 73.23 Million AUD | 87.41% |
| 2020 Q2 | 46.66 Million AUD | 0.0% |
| 2020 Q1 | 46.66 Million AUD | -4.49% |
| 2020 FY | 39.07 Million AUD | -20.02% |
| 2020 Q4 | 39.07 Million AUD | 0.0% |
| 2020 Q3 | 39.07 Million AUD | -16.26% |
| 2019 Q1 | 52.19 Million AUD | -10.79% |
| 2019 FY | 48.85 Million AUD | -16.5% |
| 2019 Q2 | 52.19 Million AUD | 0.0% |
| 2019 Q3 | 48.85 Million AUD | -6.39% |
| 2019 Q4 | 48.85 Million AUD | 0.0% |
| 2018 Q2 | 60.84 Million AUD | 0.0% |
| 2018 FY | 58.51 Million AUD | -12.13% |
| 2018 Q4 | 58.51 Million AUD | 0.0% |
| 2018 Q1 | 60.84 Million AUD | -8.63% |
| 2018 Q3 | 58.51 Million AUD | -3.84% |
| 2017 Q3 | 66.59 Million AUD | 41.91% |
| 2017 FY | 66.59 Million AUD | 12.79% |
| 2017 Q1 | 46.92 Million AUD | -20.52% |
| 2017 Q2 | 46.92 Million AUD | 0.0% |
| 2017 Q4 | 66.59 Million AUD | 0.0% |
| 2016 Q1 | 66.37 Million AUD | 49.55% |
| 2016 Q4 | 59.03 Million AUD | 0.0% |
| 2016 Q2 | 66.37 Million AUD | 0.0% |
| 2016 Q3 | 59.03 Million AUD | -11.05% |
| 2016 FY | 59.03 Million AUD | 33.02% |
| 2015 FY | 44.38 Million AUD | 20.4% |
| 2015 Q2 | 50.72 Million AUD | 0.0% |
| 2015 Q4 | 44.38 Million AUD | 0.0% |
| 2015 Q3 | 44.38 Million AUD | -12.51% |
| 2015 Q1 | 50.72 Million AUD | 37.62% |
| 2014 Q3 | 36.86 Million AUD | -17.39% |
| 2014 Q1 | 44.62 Million AUD | -8.09% |
| 2014 FY | 36.86 Million AUD | -24.07% |
| 2014 Q4 | 36.86 Million AUD | 0.0% |
| 2014 Q2 | 44.62 Million AUD | 0.0% |
| 2013 Q3 | 48.55 Million AUD | -4.87% |
| 2013 Q4 | 48.55 Million AUD | 0.0% |
| 2013 FY | 48.55 Million AUD | -10.54% |
| 2013 Q1 | 51.03 Million AUD | -5.95% |
| 2013 Q2 | 51.03 Million AUD | 0.0% |
| 2012 FY | 54.26 Million AUD | 82.06% |
| 2012 Q4 | 54.26 Million AUD | 0.0% |
| 2011 FY | 29.8 Million AUD | -20.66% |
| 2011 Q4 | 29.8 Million AUD | 0.0% |
| 2010 Q4 | 37.56 Million AUD | 0.0% |
| 2010 FY | 37.56 Million AUD | 30.23% |
| 2009 Q4 | 28.84 Million AUD | 0.0% |
| 2009 FY | 28.84 Million AUD | 17.01% |
| 2008 FY | 24.65 Million AUD | -18.97% |
| 2008 Q4 | 24.65 Million AUD | 0.0% |
| 2007 FY | 30.42 Million AUD | 21.63% |
| 2007 Q4 | 30.42 Million AUD | 0.0% |
| 2006 Q4 | 25.01 Million AUD | 0.0% |
| 2006 FY | 25.01 Million AUD | 100.11% |
| 2005 FY | 12.49 Million AUD | -32.4% |
| 2005 Q4 | 12.49 Million AUD | 0.0% |
| 2004 Q4 | 18.49 Million AUD | 0.0% |
| 2004 FY | 18.49 Million AUD | 72.56% |
| 2003 FY | 10.71 Million AUD | -43.18% |
| 2003 Q4 | 10.71 Million AUD | 0.0% |
| 2002 FY | 18.85 Million AUD | -27.53% |
| 2002 Q4 | 18.85 Million AUD | 0.0% |
| 2001 FY | 26.02 Million AUD | -10.42% |
| 2001 Q4 | 26.02 Million AUD | 0.0% |
| 2000 FY | 29.05 Million AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 1.87 Million USD | -1860.402% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -7276.979% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -13990.027% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -248.816% |
| GB Sciences, Inc. | 103.44 Thousand USD | -35489.026% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -311.368% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -205794.855% |
| Skye Bioscience, Inc. | 11.94 Million USD | -208.314% |
| Zenith Capital Corp. | 7410.00 USD | -496715.115% |
| Agentix Corp. | 261.39 Thousand USD | -13983.828% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -1780.002% |
| Biomind Labs Inc. | 73.81 Thousand USD | -49770.63% |
| ContraFect Corporation | 20.67 Million USD | -78.026% |
| CSL Limited | 38.02 Billion USD | 99.903% |
| CytoDyn Inc. | 11.13 Million USD | -230.585% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -4677.044% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -31.742% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -7560.694% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -50772.659% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -10310.699% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 71.727% |
| SQZ Biotechnologies Company | 107.18 Million USD | 65.654% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -1011.194% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 5.233% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -2470.753% |
| Mesoblast Limited | 667.9 Million USD | 94.488% |
| Marizyme, Inc. | 22.01 Million USD | -67.222% |
| Genus plc | 1.02 Billion USD | 96.422% |
| Pharming Group N.V. | 462.85 Million USD | 92.046% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -5771.451% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -9532.709% |
| IMV Inc. | 31.33 Million USD | -17.49% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -787.935% |
| MultiCell Technologies, Inc. | 126.22 USD | -29166434.622% |
| ONE Bio Corp. | 70.08 Million USD | 47.473% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 71.353% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -4.648% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -2440.924% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -22.652% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -1240.477% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -5254.873% |
| Alpha Cognition Inc. | 2.45 Million USD | -1401.283% |
| Enzolytics Inc. | 361.7 Million USD | 89.822% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.19% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 22.825% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -5655.281% |
| Genscript Biotech Corporation | 3.38 Billion USD | 98.913% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -409.906% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -48114.894% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -11339.812% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -13985.337% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -3867.193% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -2610.194% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -9330.637% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -3817.679% |
| Helix BioMedix, Inc. | 3.02 Million USD | -1116.957% |
| EV Biologics, Inc. | 431.71 Thousand USD | -8427.405% |
| Q BioMed Inc. | 3.51 Million USD | -947.186% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 30.146% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 91.751% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -152.838% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -1314.185% |
| HST Global, Inc. | 1526.00 USD | -2412350.852% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -1593579.654% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -3626.238% |
| Halberd Corporation | 10.13 Thousand USD | -363279.726% |
| Resverlogix Corp. | 8.11 Million USD | -353.654% |
| Cell Source, Inc. | 195.17 Thousand USD | -18762.433% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -161499.579% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.37 Million USD | -399.027% |
| Ember Therapeutics, Inc. | 184.00 USD | -20007508.696% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -59040.856% |
| Kadimastem Ltd | 2.3 Million USD | -1497.774% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -38385.422% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -64379.63% |
| LadRx Corporation | 2.3 Million USD | -1495.142% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -10310.699% |
| Affymax, Inc. | 7.44 Million USD | -394.612% |
| Itoco Inc. | 1.4 Million USD | -2529.436% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -34630.189% |
| Mobile Lads Corp. | 52.00 USD | -70796053.846% |
| International Stem Cell Corporation | 5.39 Million USD | -583.006% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 137.63 Thousand USD | -26646.974% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -25649.098% |
| Qrons Inc. | 420.00 USD | -8765138.095% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -9450.394% |
| SYBLEU INC | 330.46 Thousand USD | -11039.959% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -6567.753% |
| Rebus Holdings, Inc. | 5000.00 USD | -736180.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -8891.7% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -145.397% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -122.052% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -46500.0% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -4157.544% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -389.743% |
| Neutra Corp. | 2851.00 USD | -1291166.222% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -13.602% |
| PureTech Health plc | 693.97 Million USD | 94.695% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -356.122% |
| IXICO plc | 15.84 Million USD | -132.354% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -344.506% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 64.37% |
| CSL Limited | 38.02 Billion USD | 99.903% |
| Cellectis S.A. | 333.99 Million USD | 88.978% |